Dubodencel

N/A

Report date: 2026/04/28 20:00:22

First In Class

Base Information

Drug NameDubodencel

Drug Alias NameTH-1 Dendritic Cell ImmunotherapyAutologous DC vaccineAutologous dendritic cell vaccine (Diakonos Oncology)T helper type 1-autologous dendritic cell vaccine (Diakonos Oncology)DOC-1021 +[6]

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccineVaccines > Application > Therapeutic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsPancreatic NeoplasmsMelanomaGlioblastoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesDiakonos Oncology Inc

China Registration ClassN/A

Develop Information

Active CompaniesDiakonos Oncology Corp Cellipont Bioservices The Cooper Health System +[4]

Inactive CompaniesN/A

Active IndicationsPancreatic NeoplasmsMelanomaGlioblastoma +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A